Glucagon

Generic name
Glucagon
Brand name
ATC Code
H04AA01
Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

The following pharmakokinetic parameters were observed in subjects with type 1 diabetes mellitus following the subcutaneous injection of glucagon (SmPC Ogluo):

Age 2-<6 years 6-<12 years 12-<18 years
Dosage 0,5 mg 0,5 mg 1 mg
Cmax (mean) 2300 pg/mL  1600 pg/mL  1900 pg/mL
tmax  41 min 34 min (median) 51 min
AUC0-180min 138900 pg/mL*min 104700 pg/mL*min 134300 pg/mL*min

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Go to:

Diabetes, severe hypoglycaemia
  • Subcutaneous
    • < 25 kg
      [2] [6]
      • 0.5 mg/dose, once only.

      • If the cause is unknown, administering glucose is always preferred

    • ≥ 25 kg
      [2]
      • 1 mg/dose, once only. Repeat after 20 minutes if necessary..

      • If the cause is unknown, administering glucose is always preferred

  • Intramuscular
    • < 25 kg
      [2]
      • 0.5 mg/dose, once only.

      • If the cause is unknown, administering glucose is always preferred

    • ≥ 25 kg
      [2]
      • 1 mg/dose, once only. Repeat after 20 minutes if necessary.  .

      • If the cause is unknown, administering glucose is always preferred

  • Nasal
    • ≥ 4 years
      [5]
      • 3 mg/dose, once only. in one nostril.  .
Diagnostic agent: determination of C-peptide (insulin reserve)
  • Intravenous
    • 1 month up to 18 years
      [1]
      • 15 microg./kg/dose, once only. Max single dose: 1 mg/dose.
Diagnostic agent: determination of hyperinsulinism
  • Intramuscular
    • 1 month up to 18 years
      [1]
      • 0.1 mg/kg/dose, once only. Max single dose: 1 mg/dose.
Diagnostic agent: determination of GH/ACTH reserve
  • Subcutaneous
    • 1 month up to 18 years
      [3]
      • 0.1 mg/kg/dose, once only. Max single dose: 1 mg/dose.

      • Alternative administration: Intramuscular

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Injection for therapeutic use:

Very common: nausea

Common: hyperglycemia, vomiting, headache

[SmPC Ogluo]

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

GLYCOGENOLYTIC HORMONES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Novo Nordisk BV, SmPC Glucagen (RVG 02011) 22-12-2022, www.geneesmiddeleninformatiebank.nl
  3. Noordam C et al, Werkboek Kinderendocrinologie, digitale publicatie op www.nvk.nl (alleen leden), 2010
  4. Eli Lilly Nederland B.V, SmPC Baqsimi (EU/1/19/1406/001-2) 06-02-2020, www.geneesmiddeleninformatiebank.nl
  5. Eli Lilly Nederland B.V., SmPC Baqsimi® 3 mg Nasenpulver (EU/1/19/1406/001) Rev 19, 30-09-2024
  6. Tetris Pharma B.V, SmPC Ogluo (EU/1/20/1523/001; EU/1/20/1523/005) , 07-10-2024, Rev 6

Changes

Therapeutic Drug Monitoring


Overdose